VÄSTRA FRÖLUNDA, Sweden--(BUSINESS WIRE)--Artimplant (STO:ARTIB) has entered into an agreement with its licensee, Biomet Sports Medicine, Inc., to assume total responsibility for sales of ATR products.
Biomet has held the license rights for our Artelon® Tissue Reinforcement (ATR) products since 2005. During 2007, the agreement was renegotiated from exclusive to non-exclusive for the US market. In conjunction with this, Artimplant began prospecting the market independently with the aim of increasing sales of ATR products more quickly.
Biomet has held the license rights for our Artelon® Tissue Reinforcement (ATR) products since 2005. During 2007, the agreement was renegotiated from exclusive to non-exclusive for the US market. In conjunction with this, Artimplant began prospecting the market independently with the aim of increasing sales of ATR products more quickly.
